What Leqembi treats.
- Mild cognitive impairment due to Alzheimer’s disease
- Mild Alzheimer’s disease dementia
The mechanism.
Leqembi (lecanemab) is a monoclonal antibody that binds to amyloid-beta protofibrils — toxic forms of the protein that accumulate in early Alzheimer’s disease. By promoting clearance of these plaques, Leqembi has been shown to slow cognitive decline in early-stage patients.
Your Leqembi infusion experience.
Leqembi infusions are given every 2 weeks and last about 1 hour. Treatment requires confirmed amyloid pathology (via PET scan or CSF testing) and ongoing MRI monitoring for ARIA (amyloid-related imaging abnormalities). Eligibility is limited to patients in the early stages of Alzheimer’s.
Insurance & out-of-pocket cost.
Leqembi is covered by most commercial insurance and Medicare Part B when prescribed by your physician for an FDA-approved indication. We verify your benefits before your first infusion and handle prior authorization on your behalf. Most commercially insured patients pay only their standard specialty copay — typically $20–$100 per visit. Manufacturer copay assistance programs may further reduce your cost.